Thrombotic thrombocytopenia after Ad26. COV2. S vaccination KL Muir, A Kallam, SA Koepsell, K Gundabolu New England Journal of Medicine 384 (20), 1964-1965, 2021 | 442 | 2021 |
NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ... Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020 | 86 | 2020 |
T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, J Brammer, ... Journal of the National Comprehensive Cancer Network 20 (3), 285-308, 2022 | 65 | 2022 |
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 62 | 2022 |
Clear cell renal carcinoma SA Padala, A Kallam StatPearls [Internet], 2023 | 48 | 2023 |
Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, P Curtin, ... Journal of the National Comprehensive Cancer Network 19 (13), 18-21, 2020 | 46 | 2020 |
Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers ML Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ... NEJM evidence 1 (1), EVIDoa2100001, 2022 | 44 | 2022 |
HPV status and survival in non-oropharyngeal squamous cell carcinoma of the head and neck VB Wookey, AK Appiah, A Kallam, V Ernani, LM Smith, AK Ganti Anticancer research 39 (4), 1907-1914, 2019 | 39 | 2019 |
Diffuse large B cell lymphoma SA Padala, A Kallam | 37 | 2020 |
NCCN Guidelines® insights: hematopoietic growth factors, version 1.2022: featured updates to the NCCN guidelines EA Griffiths, V Roy, L Alwan, K Bachiashvili, J Baird, R Cool, S Dinner, ... Journal of the National Comprehensive Cancer Network 20 (5), 436-442, 2022 | 33 | 2022 |
Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database R Elnair, M Ellithi, A Kallam, V Shostrom, RG Bociek Annals of hematology 100, 2513-2519, 2021 | 32 | 2021 |
Recent advances in CAR-T cell therapy for non-Hodgkin lymphoma A Kallam, JM Vose Clinical Lymphoma Myeloma and Leukemia 19 (12), 751-757, 2019 | 31 | 2019 |
Identification and management of lymphedema in patients with breast cancer P Tandra, A Kallam, J Krishnamurthy Journal of oncology practice 15 (5), 255-262, 2019 | 29 | 2019 |
StatPearls SA Padala, A Kallam Treasure Island (FL), 2022 | 28 | 2022 |
VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and … M Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ... Blood 136, 13-14, 2020 | 28 | 2020 |
Physician-ordered aerosol therapy versus respiratory therapist-driven aerosol protocol: the effect on resource utilization A Kallam, K Meyerink, AM Modrykamien Respiratory Care 58 (3), 431-437, 2013 | 23 | 2013 |
Proton pump induced thrombocytopenia: A case report and review of literature A Kallam, A Singla, P Silberstein Platelets 26 (6), 598-601, 2015 | 20 | 2015 |
CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: real-world outcomes and practice patterns from 19 US academic institutions VM Orellana-Noia, DR Reed, JM Sen, C Barlow, MK Malecek, BS Kahl, ... Blood 136, 27-28, 2020 | 16 | 2020 |
P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY … M Wang, M Mei, PM Barr, J Barrientos, S de Vos, R Furman, K Patel, ... HemaSphere 6, 1116-1117, 2022 | 12 | 2022 |
Undifferentiated embryonal sarcoma of liver A Kallam, J Krishnamurthy, J Kozel, N Shonka Rare Tumors 7 (4), 130-132, 2015 | 12 | 2015 |